Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials
COVID-19 and Cancer Care
Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
The ASCO Post Staff
During the COVID-19 pandemic, would you still recommend immediate upfront autologous transplant in patients with T-cell non-Hodgkin lymphoma?
Recorded April 21, 2020.
The ASCO Post Staff
Karen E. Knudsen, PhD, MBA, Director of the Sidney Kimmel Cancer Center, talks about what she and her staff have encountered during the COVID-19 crisis and how they and their patients are coping. Filmed March 25, 2020.
The ASCO Post Staff
How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?
Recorded April 24, 2020.
The ASCO Post Staff
Derek Raghavan, MD, PhD, of the Levine Cancer Institute in Charlotte, and a member of The ASCO Post Editorial Board, discusses the ways in which COVID-19 has affected oncology care in his community, and some practical tips that may help fellow providers. Filmed April 9, 2020.
The ASCO Post Staff
Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.